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Conventional therapy for non–ST-segment elevation acute coronary syndrome (ACS) has
traditionally employed an “ischemia-guided” strategy. In this approach, diagnostic cardiac
catheterization and revascularization are only used in patients with objective evidence of
myocardial ischemia as identified by recurrent symptoms or provocative stress testing. More
recent studies, however, have demonstrated improved clinical outcomes with the use of an
“early invasive” approach, employing routine coronary angiography early in the patient’s
hospital course, followed by percutaneous intervention or bypass surgery where appropriate.
Improved clinical outcomes associated with an “early invasive” strategy may have evolved as
a consequence of recent advances in both adjunctive pharmacotherapy and revascularization
technique. In particular, use of glycoprotein IIb/IIIa inhibitors and/or low-molecular-weight
heparin before catheterization have been shown to reduce clinical events in patients with
ACS, and may reduce the risk of an invasive approach by plaque passivation before
interventional therapy. Perhaps more importantly, the combined use of glycoprotein IIb/IIIa
inhibitors and intracoronary stenting may reduce the potential early hazard of an invasive
approach by specifically decreasing the incidence of death and nonfatal myocardial infarction
associated with percutaneous intervention. In spite of the benefits of this synergistic
combination of pharmacology and mechanical revascularization, risk stratification remains
important in identifying high-risk individuals most likely to benefit from an “early invasive”
approach. In addition, angiography with possible percutaneous coronary intervention of
“culprit” lesions should always be used in combination with aggressive medical therapy to treat
the widespread coronary atherosclerosis commonly seen in patients with ACS. (J Am Coll
Cardiol 2003;41:96S–102S) © 2003 by the American College of Cardiology Foundation
Two general approaches have evolved for patients with
unstable angina and non–ST-segment elevation myocardial
infarction (NSTEMI). Conventional therapy of NSTE
acute coronary syndrome (ACS) has mainly involved the
rapid initiation of intensive medical management, followed
by noninvasive risk stratification to identify those who need
catheterization and possible revascularization versus those
who can continue with medical therapy alone. This
“ischemia-guided” approach differs from an “early invasive”
approach in which noninvasive testing is deferred, and all
patients with suspected ACS are referred for coronary
angiography and possible revascularization early in their
hospital course. The debate over the relative superiority of
these two treatment strategies has been longstanding and
has been further fueled by the results of several recent
clinical trials.
Proponents of the “ischemia-guided” approach argue that
intensive medical therapy, particularly in patients who have
not been previously treated with aggressive antiplatelet,
antithrombotic, anti-ischemic and lipid-lowering agents,
may result in rapid clinical stabilization. Exercise stress
testing in its various forms (i.e., treadmill exercise or
pharmacologic vasodilator stress testing with myocardial
perfusion imaging) may then reliably identify those patients
at risk for future events who need to undertake the risk of
cardiac catheterization and subsequent revascularization.
This approach—tailoring therapy to risk—optimizes clini-
cal efficacy and cost-effectiveness because high-risk patients
are identified and treated, while low-risk patients avoid
costly invasive procedures that are unlikely to confer clinical
benefit and may actually cause harm.
Alternatively, it has been argued that an “early invasive”
approach can accurately determine coronary anatomy early
in the patient’s hospital course, thus avoiding lengthy delays
and possible ambiguities sometimes associated with nonin-
vasive testing. Specific anatomical subgroups can be expe-
ditiously identified and treated. These include patients with
normal coronary arteries and minimal disease who can be
discharged home, and also patients with left main stenoses,
three-vessel disease, or multivessel disease with decreased
left ventricular function who would benefit from bypass
surgery. The remaining patients can be risk-stratified and
treated according to their angiographic findings, with ap-
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propriate use of percutaneous coronary intervention (PCI)
as indicated by angiography, intravascular ultrasound,
and/or Doppler blood flow and pressure measurements.
Over the last seven years, four major randomized studies
have examined the relative benefits of an “ischemia-guided”
versus “early invasive” approach. These include: the Throm-
bolysis In Myocardial Infarction (TIMI)-IIIB (1); the
Veterans Affairs Non–Q-Wave Infarction Strategies in
Hospital (VANQWISH) (2); the Fragmin and fast Revas-
cularization during InStability in Coronary artery disease
(FRISC) II (3); and the Treat Angina with Aggrastat and
determine Cost of Therapy with an Invasive or Conservative
Strategy (TACTICS) TIMI-18 (4) trials. Conclusions de-
rived from TIMI-IIIB and VANQWISH have been the
primary basis for the current use of “ischemia-guided”
therapy. In contrast, FRISC II and TACTICS have, more
recently, identified possible advantages of an “early invasive”
approach. Differing conclusions reached by these studies
may have been a natural consequence of the recent rapid
advances in both adjunctive pharmacotherapy and revascu-
larization techniques.
The TIMI-IIIB trial. Published in 1994, the TIMI-IIIB
trial (1) was designed to evaluate the effect of a fibrinolytic
agent added to conventional medical therapies and to
compare an early invasive with an early conservative ap-
proach in the management of patients with unstable angina
or non–Q-wave MI. Using a 2  2 factorial design, 1,425
patients were randomized to receive either tissue-
plasminogen activator or placebo and either an early invasive
strategy or an early conservative therapy. Patients random-
ized to the early invasive strategy underwent routine coro-
nary angiography 18 to 48 h after randomization, with use
of percutaneous transluminal coronary angioplasty (PTCA)
or coronary artery bypass graft (CABG) surgery depending
upon coronary anatomy. Patients randomized to conserva-
tive therapy were treated with initial medical therapy, with
subsequent angiography and revascularization only for re-
current rest ischemia (defined by chest pain, electrocardio-
gram [ECG] changes, or ST-segment depression on Holter
monitoring), or for ischemia on a predischarge thallium
stress test. All patients were treated with intravenous hep-
arin, aspirin, beta-blockers, nitrates, and calcium antago-
nists, as clinically indicated.
In the early invasive strategy, coronary angiography was
performed in 98% of patients, with revascularization in 61%
of patients within 6 weeks (PTCA in 38% and CABG in
25%). In the conservative strategy arm, angiography was
performed in 64% of patients, with revascularization in 49%
by 6 weeks, including PTCA in 26% and CABG in 24%. By
1 year, the difference in the rates of revascularization became
even smaller, with 64% in the early invasive strategy and
58% in the conservative strategy. This small difference was
primarily due to differences in the use of PTCA (39% invasive
vs. 32% conservative, p  0.001), with no significant differ-
ences in the use of bypass surgery (30% in each group).
At six weeks there was no significant difference in the
primary end point—defined as the composite incidence of
death, postrandomization nonfatal MI, or a positive stress
test—between conservative or invasive strategies (18.1% for
the conservative therapy vs. 16.2% for the early invasive
strategy, p  NS). The overall incidence of death (2.4%)
and MI (6.3%) were low, with no significant differences
between the two strategies. Patients in the early invasive
therapy had a shorter initial hospitalization, less frequent
rehospitalization, fewer days of rehospitalization, and re-
quired less antianginal medications at their six-week evalu-
ation.
At 1 year the incidence of mortality for all patients
increased to 4.3% while nonfatal MI increased to 8.8%.
Again, there was no significant difference in the combined
incidence of death and nonfatal MI between the two
strategies (10.8% in the early invasive group vs. 12.2% in the
early conservative group, p  NS). However, a prespecified
subgroup analysis did show a benefit for the invasive
approach in higher-risk patients (including patients with
ECG changes, elevated cardiac enzymes, female gender,
and age 65 years). Also, patients in the early invasive arm
required less hospitalization.
Based on these results, the TIMI-IIIB authors concluded
that an early invasive strategy provided more rapid and
effective relief of angina in patients with non–ST-segment
elevation ACS than a conservative strategy, but that equiv-
alent early and late outcomes were achieved with the two
approaches with respect to death and MI. Given the similar
outcomes with the two different strategies, patients could be
managed individually depending upon the severity of their
presentation, cardiac risk factors, left ventricular function,
and response to medical therapy.
The VANQWISH trial. Published in 1997, the VAN-
QWISH trial randomized 920 non–Q-wave MI patients
from 17 Veterans Affairs medical centers to an early invasive
or an early conservative strategy between April 1993 and
December 1995 (2). Patients in the early invasive arm
underwent coronary angiography within one to three days
after hospital admission, while patients in the conservative
arm were treated with medical therapy and underwent
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
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CABG  coronary artery bypass graft
ECG  electrocardiogram
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NSTEMI  non–ST-segment elevation myocardial
infarction
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catheterization only for spontaneous post-MI angina or for
an abnormal predischarge thallium stress test. Of note, the
early invasive strategy did not require myocardial revascu-
larization. All patients were treated with aspirin and dilti-
azem, with use of heparin, nitrates, beta-blockers, and
angiotensin-converting enzyme (ACE) inhibitors as clini-
cally indicated.
In the early invasive strategy, coronary angiography was
performed in 96% of patients. Revascularization was done in
44%, including PTCA in 48%, CABG in 47%, and both in
5%. In the conservative strategy arm, angiography was
performed in 48% of patients, with revascularization in 33%,
including PTCA in 36%, CABG in 57%, and both in 7%.
The primary end point of the study was the combination
of mortality and nonfatal MI during at least 12 months
follow-up. At the time of hospital discharge, at one month
and at one year, clinical outcomes were significantly better
in the early conservative arm compared with the early
invasive arm. There was a 1.3% mortality risk in the
conservatively managed patients compared with 4.5% in the
invasive group at hospital discharge (p  0.007), 1.9%
versus 4.9% at 1 month (p  0.02), and 7.8% versus 12.5%
at 1 year (p  0.025), respectively. Similarly, for combined
mortality and nonfatal MI, conservative compared with
invasive results were 3.3% versus 7.7% at hospital discharge
(p  0.004), 5.6% versus 10.3% at 1 month (p  0.012),
and 18.5% versus 24.0% at 1 year (p  0.05). The increase
in mortality in the early invasive arms was primarily attrib-
uted to a high rate of in-hospital mortality for bypass
surgery (30-day mortality after CABG surgery was 7.7%).
After hospital discharge there was no significant difference
in the death or reinfarction rates between the two revascu-
larization modalities. Moreover, by 23 months of follow-up,
there was no significant difference in the combined end
point of death and MI between the two groups: 29.9% in
the early invasive group versus 26.9% in the conservative
treatment group.
Based on these results, the VANQWISH investigators
concluded that the early conservative approach was the
preferred treatment strategy for patients with non–Q-wave
MI. The authors did not comment upon the effect of the
two therapies on the extent of symptom relief.
The FRISC II trial. The FRISC II trial randomized 2,457
patients with unstable angina and NSTEMI in 58 Scandi-
navian hospitals to an early invasive strategy or to an
ischemia-guided approach, with placebo-controlled long-
term low-molecular-weight heparin (dalteparin) for 3
months. Patients in the early invasive group underwent
catheterization followed by revascularization within seven
days, while ischemia-guided patients underwent angiogra-
phy only if they had recurrent angina or severe ischemia on
a symptom-limited exercise tolerance test. Patients in the
invasive arm were treated with dalteparin until revascular-
ization, while patients in the ischemia-guided arm received
the drug for at least five days. The NSTEMI was diagnosed
by elevated troponin T (0.1 g/l) in 57% of patients in the
early invasive group and 58% of patients in the ischemia-
guided group.
In the early invasive arm, 98% of patients underwent
coronary angiography, with subsequent revascularization in
78%, including PCI in 44% and CABG in 34%. In the
ischemia-guided arm, 38% underwent angiography, fol-
lowed by revascularization in 37%, including PCI in 18%
and CABG in 19%. Most of these procedures (80%) were
performed within 10 days in the early invasive group, while
only a minority (20%) of patients in the ischemia-guided
group had CABG or PCI within 10 days of randomization.
Stenting was used in 61% of the PCI procedures in the
invasive group and in 70% of the PCI procedures in the
ischemia-guided group. About 10% of patients in both
groups were treated with abciximab.
The primary end point of the study was the combination
of death and nonfatal MI. At 6 months the rate of death or
MI was 9.4% in the early invasive group and 12.1% in the
ischemia-guided patients (relative risk [RR], 0.78; 95%
confidence interval [CI], 0.62 to 0.98). For death alone, the
difference between the groups was less impressive, but still
favored an early invasive approach (1.9% vs. 2.9%; RR, 0.65;
95% CI, 0.39 to 1.09).
Subset analysis showed no evidence of a beneficial effect
of an early invasive strategy in women, while the invasive
strategy resulted in a highly significant 34% reduction in the
combined end point (p  0.002) and a significant 52%
reduction in mortality from 3.2% to 1.5% (p  0.03) in
men. For both men and women, the early invasive strategy
provided a 50% relative reduction in symptoms of angina
and need for hospital readmission during the 6-month
follow-up.
The TACTICS TIMI-18 trial. The TACTICS TIMI-18
trial was designed to evaluate the upstream use of tirofiban
in NSTE ACS patients combined with an “early invasive”
approach using diagnostic catheterization and PCI (4). The
trial included 2,220 patients with unstable angina or
NSTEMI who had either ECG changes, elevated cardiac
markers, and/or a prior history of coronary artery disease.
All patients were initially treated with aspirin, heparin, and
tirofiban. They were then randomized to either early diag-
nostic catheterization (within 4 to 48 h) and revasculariza-
tion as indicated, or to a more conservative approach with
invasive procedures performed only if the patient had
objective evidence of residual ischemia with recurrent an-
gina or a positive stress test. Electrocardiographic changes
were present in 48% of patients, while 54% of the study
group had elevated troponin T levels.
In the early invasive strategy group, coronary angiography
was carried out in 97% of patients, with revascularization
performed in 61%, including PTCA in 41% and CABG in
20%. In the conservative strategy arm, angiography was
performed in 51% of patients, with revascularization in 37%,
including PTCA in 24% and CABG in 13%. Coronary
stents were used during PCI procedures in 83% of the early
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invasive group and in 85% of the conservative treatment
patients.
The primary end point of the study was a composite of
death, nonfatal MI, or rehospitalization for an ACS at six
months. This end point was reduced from 19.4% with the
conservative approach to 15.9% with the early invasive
strategy (p  0.025), with similar significant reductions in
death or MI from 9.5% to 7.3% (p  0.0498). This benefit
of an early invasive approach was largely confined to patients
who were troponin-positive or who had ST-segment de-
pression on their admission ECG.
Understanding the differences between trials. Compared
with TIMI-IIIB and VANQWISH, the FRISC II and
TACTICS trials showed, for the first time, a significantly
lower cardiac event rate in NSTE ACS patients referred for
an early invasive approach compared with an ischemia-
guided strategy. Both studies clearly demonstrated a signif-
icant reduction in the composite incidence of death and
nonfatal MI at six months in early invasive patients com-
pared with their ischemia-guided counterparts. These re-
sults differ sharply from the TIMI-IIIB results in which
there were no significant differences in strategy outcomes,
and from VANQWISH, in which ischemia-guided therapy
was clearly favored.
Differences in outcomes for these four studies may be
related, in part, to specific aspects of trial design or to
deficiencies in study implementation. For example, in the
TIMI-IIIB trial, the study’s outcomes may have been
adversely affected by the administration of fibrinolytic ther-
apy in 50% of patients, potentially resulting in lysis-induced
platelet activation, which raised the risk for PCI. Similarly,
proponents of the early invasive approach cite the high
surgical mortality in the early invasive arm of the VAN-
QWISH trial as an outlying factor that is the principal cause
for the study’s conclusions. Finally, proponents of the
ischemia-guided strategy are critical of the noninvasive arm
of the FRISC II trial because the study design used strict
criteria on standard exercise testing rather than myocardial
perfusion imaging to identify patients who required cathe-
terization and possible revascularization.
In addition to these trial-specific criticisms, another
possible basis for the different trial outcomes relates to the
absolute revascularization rates among patients. Comparing
ischemia-guided to early invasive groups, the revasculariza-
tion rates were 49% versus 61% in TIMI-IIIB, 33% versus
44% in VANQWISH, 37% versus 78% in FRISC II, and
37% versus 61% in TACTICS. It is clear that the differ-
ences in absolute revascularization rates were smaller in
TIMI-IIIB and VANQWISH, raising the possibility that
these two studies were insufficiently powered to detect
significant differences between ischemia-guided and early
invasive strategies.
Apart from the considerations described in the preceding
text, perhaps the most important differences between earlier
and more recent studies is that FRISC II and TACTICS
have incorporated improvements in both adjunctive phar-
macotherapy and revascularization technique that may have
made an “early invasive” approach safer and more effective.
These include the use of low-molecular-weight heparin,
glycoprotein (GP) IIb/IIIa inhibitors, and intracoronary
stents, as well as improvements in anesthesiology and
CABG techniques. Low-molecular-weight heparin, GP
IIb/IIIa inhibitors, and intracoronary stents were not avail-
able in the TIMI-IIIB and VANQWISH trials because
enrollment was completed before 1995.
Decreasing the hazards of PCI. The presence of unstable
angina has long been recognized as a risk factor for PCI in
the cardiac catheterization laboratory. Previous studies in-
volving conventional balloon angioplasty have clearly docu-
mented an increased risk of major complications in patients
with unstable versus stable angina, including an increased
risk of Q-wave MI, emergency CABG surgery, and death
(5–7). Based on this increased complication rate, a specific
“early hazard of intervention” has been defined for PCI in
the ACS patient. Proposed pathophysiologic causes include
plaque rupture within an epicardial vessel with variable
amounts of thrombus that may propagate or embolize to the
distal vasculature, as well as the inherent deficiencies of
conventional balloon angioplasty in achieving stable lumen
enlargement.
Theoretically, the risk of an early invasive approach in
NSTE ACS might be reduced by both preprocedure plaque
passivation to reduce thrombus and by specific procedural
measures to reduce the incidence of complications in the
catheterization laboratory. In this regard, newer antithrom-
botic and antiplatelet agents given “upstream” before and
during cardiac catheterization, as well as use of newer
mechanical revascularization techniques at the time of
intervention, may be expected to affect outcomes.
Based on the TIMI-IIB (8) and the Efficacy and Safety of
Subcutaneous Enoxaparin in Non–Q-wave Coronary
Events (ESSENCE) (9) trials, low-molecular-weight hep-
arin has clearly been shown to provide clinical benefit as
“upstream” therapy for patients with NSTE ACS. In a
meta-analysis of ACS patient data from these two trials
(10), enoxaparin was shown to result in a 20% reduction in
death or serious cardiac ischemic events compared with
unfractionated heparin. This clinical benefit was evident
within the first few days of treatment and persisted for 43
days after enrollment. A similar potential benefit of dalte-
parin was evident in the FRISC II trial. In terms of the
effect of dalteparin during three months of double-blind
treatment, there was a significant decrease in the composite
end point of death and MI in favor of dalteparin over
placebo (6.7% vs. 8.0%). While this benefit is conveyed to
all ACS patients, it may have specifically improved out-
comes in “early” invasive patients by improving plaque
passivation before PCI, leading to less serious clinical
events.
More convincing data are evident with respect to the GP
IIb/IIIa inhibitors. The clinical benefit of GP IIb/IIIa
inhibitors has been incontrovertibly tested over the last
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decade, both in unstable angina patients before intervention
and during PCI (11–14). Based upon data from over 24,000
patients, clinical trials have demonstrated that treatment of
NSTE ACS patients with GP IIb/IIIa agents results in an
approximate 12% RR reduction for the incidence of death
or MI at 30 days (15,16). More importantly, based upon the
Platelet glycoprotein IIb/IIIa in Unstable Angina: Receptor
Suppression Using Integrelin Therapy (PURSUIT), the
Platelet Receptor Inhibition in Ischemic Syndrome Man-
agement in Patients Limited by Unstable Signs and symp-
toms (PRISM-PLUS), and the Platelet IIb/IIIa Antagonist
for the Reduction of Acute coronary syndrome events in a
Global Organization Network (PARAGON) B trials, the
benefits of GP IIb/IIIa agents also appear to be magnified in
NSTE ACS patients referred for early cardiac catheteriza-
tion and PCI. Comparing the composite outcome of 30-day
death or MI among patients referred for PCI versus those
who did not undergo intervention, the RR reduction with
GP IIb/IIIa use was 31% versus 6% for PURSUIT, 42%
versus 12% for PRISM-PLUS, and 35% versus 7% for
PARAGON B (16).
Apart from antithrombotic and antiplatelet advances,
improvements in mechanical revascularization may account
for improved outcomes in the FRISC II and TACTICS
trials. In particular, stenting has emerged as the preferred
PCI approach, with reductions in repeat target vessel
revascularization and angiographic restenosis (17), and with
a synergistic improvement in clinical outcomes when com-
bined with GP IIb/IIIa inhibition (18). The specific advan-
tage of stenting versus PTCA in patients with unstable
angina was recently examined at the Mayo Clinic. In this
retrospective study of over 7,600 patients, significant de-
creases in in-hospital mortality and emergency CABG were
found, as well significant reductions in Q-wave MI, CABG
surgery, and recurrent angina at one year (19). In addition to
stenting, other revascularization techniques are currently
being investigated that may have an impact on outcomes.
These include percutaneous thrombectomy catheters and
embolic protection devices.
The benefits from new advances in pharmacotherapy and
revascularization techniques for the early invasive approach
are most apparent in the TACTICS TIMI-18 trial. Using
GP IIb/IIIa inhibition in all patients and intracoronary
stents in most, an extremely low (4.7%) absolute rate of
death or nonfatal MI at 30 days was found in the early
invasive patients. As noted by the study’s authors, this
represents the lowest rate in any ACS trial reported to date.
Most importantly, compared with the TIMI-IIIB, VAN-
QWISH, and FRISC II trials (each of which showed an
increased incidence of MI and combined death/MI within
the first seven days in the “early invasive” group), there was
no “early hazard” observed with PCI in the TACTICS
TIMI-18 patients. Tirofiban treatment may have mitigated
the consequences of incomplete platelet inhibition that led
to excess in-hospital events observed in earlier studies, while
intracoronary stenting probably provided for a more stable
angiographic result.
Continued need for risk stratification. While TACTICS
and FRISC II provide growing impetus for a combined
pharmacologic and interventional approach, these studies
underscore previous conclusions from TIMI-IIIB and
VANQWISH regarding the value of risk stratification in
delineating subgroups most likely (or unlikely) to benefit
from early intervention. For example, both FRISC-II and
TACTICS TIMI-18 demonstrate a concordance of benefit
with the “early invasive” strategy in high-risk, troponin-
positive patients, with a neutral effect among troponin-
negative subjects, and little benefit in lower-risk patients.
Similarly, “early invasive” benefits were largely confined to
patients with ST-segment depression on the admission
ECG. With the advent of “point-of-care” troponin testing
in the emergency department, together with routine ECG,
rapid identification of those high-risk patients most likely to
benefit from an “early invasive” approach is readily feasible.
Continued need for aggressive medical therapy. In addi-
tion to recognizing the importance of risk stratification, an
early invasive approach should not be considered as an
alternative to complementary aggressive medical therapy.
Such therapy should be administered to all ACS patients
and should include aspirin (with or without clopidogrel),
beta-blockade, anti-thrombotic therapy with unfractionated
or low-molecular-weight heparin, nitrates, GP IIb/IIIa
inhibitors, statins, and ACE inhibitors.
Most patients with ACS have diffuse systemic atheroscle-
rosis that involves the entire coronary vascular system.
Angiography is only capable of measuring cross-sectional
anatomy from a simple planar two-dimensional silhouette of
the contrast-filled lumen and, therefore, may grossly under-
estimate plaque burden and the true extent of atherosclero-
sis (20–22). Individual lesion assessment may be particularly
difficult if adjacent “normal” arterial segments are diffusely
diseased, or if there has been significant coronary remodel-
ing with the development of “extraluminal” plaques.
In addition to underestimating disease severity, angiog-
raphy is similarly incapable of assessing plaque vulnerability
and the subsequent risk for plaque rupture. Previous studies
have clearly demonstrated that most coronary occlusions
and MIs occur at sites where angiography has previously
identified mild or moderate stenoses, with few acute syn-
dromes evolving from high-grade lesions (23). Perhaps
more importantly, more recent studies have suggested that
ACS patients may have multiple sites of plaque ulceration
that may subsequently result in plaque rupture (24,25).
Given the diffuse nature of coronary atherosclerosis and
the limitations of angiography in identifying plaque burden
and lesions prone to plaque rupture, it follows that all ACS
patients should be treated with aggressive medical therapy,
whether or not cardiac catheterization and PCI is used. The
theoretical benefit of such therapy, particularly with statins,
beta-blockers, and ACE inhibitors, is that there may be
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underlying stabilization of atherosclerotic plaque through-
out the coronary vasculature (26,27).
Conclusions. While the debate over the relative superiority
of an ischemia-guided versus an early invasive approach
remains unsettled, it is clear that recent studies, including
FRISC II and TACTICS TIMI-18, have demonstrated
improved clinical outcomes in NSTE ACS patients with
routine use of diagnostic catheterization and revasculariza-
tion as indicated. Apart from the fact that these recent
studies have been appropriately powered to determine po-
tential differences between the two treatment strategies, an
important component of their findings has been their
incorporation of newer antiplatelet and antithrombotic
agents and intracoronary stenting into study protocols. Use
of these newer modalities has improved clinical outcomes
before catheterization and during PCI.
In spite of the benefits of an early invasive approach
observed in FRISC II and TACTICS TIMI-18, both
studies clearly demonstrated the continued need for risk
stratification. In particular, using point-of-care testing, such
stratification can identify high-risk patients most likely to
benefit from an invasive approach. These high-risk at-
tributes include a history of chest pain at rest, ST-segment
depression on the ECG, positive cardiac markers of isch-
emic injury (e.g., creatine kinase myocardial band isoen-
zyme, troponin, myoglobin), evidence of hemodynamic
instability or ventricular dysfunction, and a prior history of
PCI or bypass surgery.
The debate over the routine use of coronary angiography,
however, continues for patients who are considered low- or
intermediate-risk, including for those with normal ECG or
nonspecific ECG changes and for those without biomarker
positivity. In spite of FRISC II and TACTICS, an “early
invasive” approach does not appear to be warranted in this
subclass of patients. Optimal therapy continues to involve
noninvasive testing for risk stratification, which minimizes
the early hazard of revascularization in patients without
significant myocardium at risk or recurrent symptoms.
Alternatively, it is also important to make the distinction in
the “early invasive” strategy between coronary angiography
per se and angiography leading to percutaneous interven-
tion. While there was no apparent advantage to an invasive
approach in the troponin-negative, non–ST-segment de-
pression group in TACTICS TIMI-18, there was also no
added harm. Angiography alone, despite its limitations, can
often serve as a powerful risk-stratification technique to
obtain useful anatomic information in a wide range of
difficult patient subsets, ranging from low-risk patients with
unremitting symptoms and inconclusive noninvasive tests to
higher-risk patients (i.e., diabetics) with atypical presenta-
tions.
Finally, regardless of the use of cardiac catheterization
and possible PCI, all clinicians certainly agree that sus-
pected ACS patients should be treated aggressively with
medical therapy as clinically indicated. The diffuse nature of
coronary atherosclerosis and the inherent limitations of
coronary angiography in determining plaque burden and
vulnerability necessitate the appropriate use of such therapy
to decrease the incidence of MI and death in the ACS
setting.
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